General Information of Drug (ID: DMF4I1V)

Drug Name
FT-0710230 Drug Info
Synonyms
Meconic acid; Mekonsaure; NSC 805; NSC-805; NSC805; Opium acid; Poppy acid; Q421116; SCHEMBL546968; SCHEMBL600257; UNII-V502I79516; V502I79516; ZEGRKMXCOCRTCS-UHFFFAOYSA-N; ZINC1587602; Opio; Papaver somniferum exudate; Papaver somniferum resin; 3-HYDROXY-4-OXO-4H-PYRAN-2,6-DICARBOXYLIC ACID; 3-Hydroxy-4-oxo-1,4-pyran-2,6-dicarboxylic acid; 3-Hydroxy-4-oxopyran-2,6-dicarboxylic acid; 3-hydroxy-4-oxo-pyran-2,6-dicarboxylic acid; 3-hydroxy-4-pyrone-2,6-dicarboxylic acid; 497-59-6; 4H-Pyran-2, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylic acid, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylicacid, 3-hydroxy-4-oxo-; BDBM50147502; C20209; CHEMBL109516; CTK1D7773; DB-083476; DTXSID2060096; EINECS 207-848-2
Cross-matching ID
PubChem CID
10347
TTD Drug ID
DMF4I1V
INTEDE Drug ID
DR1203

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
Drug Status:
Approved Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [2]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [3]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [4]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [5]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [6]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [7]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [8]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [9]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [10]
Propranolol DM79NTF Angina pectoris BA40 Approved [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [1]

References

1 Interpretation of opiate urine drug screens.
2 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
3 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
4 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
5 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
6 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
7 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
8 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
9 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
10 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
11 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.